Belgium

UCB SA Monitor

UCB SA Annual Report 2017
CR Monitor Issue: 
2018/0611
Company covered: 
UCB SA
Period End: 
31 December, 2017
Report issued on 19 June 2018 covered the following practice issues:
Pronouncements
Early adoption of IFRS 15 "Revenue from contracts with customers" using a full retrospective approach.
Pronouncements
Enhanced disclosure in respect of the future impacts of IFRS 16 "Leases".
Change
Fair value of previously held interest in business acquired taken into account in calculation of goodwill.
Pronouncements
Presentation of a reconciliation of movements in liabilities arising from financing activities on adoption of amendment to IAS 7 "Statement of cash flows".
Change
Discussion of key audit matters included in the auditors' report.
Change
Extended disclosure of principal risks including identification of a new risk factor.

Umicore SA Monitor

Umicore SA Annual Report 2017
CR Monitor Issue: 
2018/0607
Company covered: 
Umicore SA
Period End: 
31 December, 2017
Report issued on 12 June 2018 covered the following practice issues:
Change
Bargain purchase resulting in recognition of business acquisition gain.
Change
Business acquisition loss recognised in respect of acquisition achieved in stages.
Change
Disclosure of share issue and a business acquisition and disposal in a post balance sheet events note.
Pronouncements
Disclosure included in respect of IFRIC 23 "Uncertainty over income tax treatments"

Fair value measurement information under IFRS

IFRS 13 “Fair value measurement” sets out a single consistent framework for measuring fair value within IFRS financial statements and outlines a standardised set of disclosures in respect of fair value measurements. IFRS 13 has been mandatory now for some years, with application being required for annual reporting periods beginning on or after 1 January 2013. This report sets out the results of how requirements of the standard have been put into practice, both in terms of measurement and disclosure, in the consolidated financial statements of 139 large public limited companies with year ends between 31 March 2016 and 1 April 2017. It is not an exhaustive study of all aspects of IFRS 13 application and its conclusions are limited to our findings in respect of the areas analysed within the financial statements reviewed.

Etn. Fr. Colruyt NV Monitor

Etn. Fr. Colruyt NV Annual Report 2016
CR Monitor Issue: 
2016/0910
Company covered: 
Etn. Fr. Colruyt NV
Period End: 
31 March, 2016
Report issued on 27 September 2016 covered the following practice issues:
Change
Allocation of costs to individual reporting segments results in restatement.
Change
Disclosure of indefinite lived intangible assets by cash generating unit.
Restatement
Reclassification of items in cash flow statement without full explanation results in restatement.

Inventories - UCB SA

Period End: 
31 December, 2015
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4573 Biotechnology
Auditor: 
PricewaterhouseCoopers

Financial instruments - Colruyt NV

Period End: 
31 March 2015
Period End Date: 
2015-03-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
5337 Food Retailers & Wholesalers
Auditor: 
KPMG

R&D tax and expenditure credits: an emerging issue under IFRS

This report addresses accounting for the new research and development (R&D) expenditure credit (RDEC) available from Her Majesty's Revenue and Customs (HMRC), the responsible tax authority in the United Kingdom, the previous UK scheme still in force for some companies and a similar scheme in Europe.

Accounting estimates and judgements - UCB

Period End: 
31 December 2014
Period End Date: 
2015-12-31
Listing Status: 
S&P Europe 350
ICB Industry Classification: 
4577 Pharmaceuticals
Auditor: 
PricewaterhouseCoopers
Annual Report: 

Investment entities exemption to consolidation: an emerging issue under IFRS

This report looks at the application of the Investment entities exemption to the consolidation requirements of IFRS 10 "Consolidated financial statements". We examine the scope of the exemption, related disclosures and the principal effects on the primary statements.